Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Attention Deficit Hyperactivity Disorder (ADHD) - Market Insights, Epidemiology and Market Forecast to 2027 - ResearchAndMarkets.com

Research and Markets
Posted on: 30 Nov 18

The "Attention Deficit Hyperactivity Disorder (ADHD) - Market Insights, Epidemiology and Market Forecast-2027" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Attention Deficit Hyperactivity Disorder (ADHD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Attention Deficit Hyperactivity Disorder (ADHD) from 2016 to 2027 segmented by seven major markets.

The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Disease Understanding & Treatment Algorithm

According to American Psychiatric Association, Attention Deficit Hyperactivity Disorder (ADHD) is a brain/neurodevelopmental/neurobehavioral disorder and is one of the most common mental disorders affecting children. The disease also affects many adults. Symptoms of Attention Deficit Hyperactivity Disorder (ADHD) include inattention (not being able to keep focus), hyperactivity (excess movement that is not fitting to the setting) and impulsivity (hasty acts that occur in the moment without thought).

According to National Institute of Mental Health, Inattention and hyperactivity/impulsivity are the key behaviors of Attention Deficit Hyperactivity Disorder (ADHD). Some people with Attention Deficit Hyperactivity Disorder (ADHD) only have problems with one of the behaviors, while others have both inattention and hyperactivity-impulsivity. Most children have the combined type of Attention Deficit Hyperactivity Disorder (ADHD). ADHD is diagnosed as one of three types: inattentive type, hyperactive/impulsive type or combined type.

The Attention Deficit Hyperactivity Disorder (ADHD) market report gives the thorough understanding of the ADHD by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Attention Deficit Hyperactivity Disorder (ADHD) in the US, Europe, and Japan.

Epidemiology

The Attention Deficit Hyperactivity Disorder (ADHD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Prevalence of Attention Deficit Hyperactivity Disorder (ADHD), Age specific prevalent cases of Attention Deficit Hyperactivity Disorder (ADHD), Diagnosed and Treatable Cases of Attention Deficit Hyperactivity Disorder (ADHD)] scenario of Attention Deficit Hyperactivity Disorder (ADHD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027.

According to National Institute of Mental Health, the prevalence of children ever diagnosed with ADHD increased by 42% between 2003 (7.8%) and 2011 (11.0%).

As per National Comorbidity Survey-Adolescent Supplement (NCS-A), the lifetime prevalence of ADHD among U.S. adolescents aged 13 to 18 years was found to be 8.7%.

According to National Resource Center on ADHD, the estimates of worldwide adult ADHD prevalence averaged 3.4%.

According to ADHD Institute, meta-regression analyses have estimated the worldwide ADHD prevalence between 5.29% and 7.1% in children and adolescents, and at 3.4% (range 1.2-7.3%) in adults. The prevalence of Attention-deficit hyperactivity disorder (ADHD) is greater in males (60%) than females (40%).

Other Chapters

  • Drug Chapters
  • Market Outlook
  • Drugs Uptake

Companies Featured

  • Sunovion
  • NeuroDerm

Key Topics Covered

1. Report Introduction

2. Attention Deficit Hyperactivity Disorder (ADHD) Market Overview at a Glance

3. Disease Background and Overview: Attention Deficit Hyperactivity Disorder (ADHD)

4. Epidemiology and Patient Population

5. Treatments & Medical Practices

6. Marketed drugs

7. Emerging Therapies

8. Attention Deficit Hyperactivity Disorder (ADHD) Market Size

9. 7MM Attention Deficit Hyperactivity Disorder (ADHD): Country-Wise Market Analysis

10. United States Market Size

11. Germany Market Size

12. France Market Size

13. United Kingdom Market Size

14. Spain Market Size

15. Italy Market Size

16. Japan Market Size

17. Market Drivers

18. Market Barriers

19. Report Methodology

20. Capabilities

For more information about this report visit https://www.researchandmarkets.com/research/3kfglk/attention_deficit?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181130005249/en/

Business Wire
www.businesswire.com

Last updated on: 30/11/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.